906.2500 -7.30 (-0.80%)
NSE Nov 19, 2025 15:58 PM
Volume: 63,911
 

906.25
-0.80%
BOB Capital Markets Ltd.
Revenue/EBITDA/ PAT grew 6.7%/8% and 19% above our estimates. EBITDA margin reported 20bps above estimates of 15.4% in 4QFY25
Alembic Pharmaceuticals Ltd. is trading below all available SMAs
More from Alembic Pharmaceuticals Ltd.
Recommended